Gavreto (pralsetinib) for the Treatment of Non-Small Cell Lung Cancer (NSCLC)

Image 3- Gavreto (pralsetinib)
NSCLC accounts for 80% to 85% of all lung cancers. Credit: Douglas Olivares/Shutterstock.